An employee with persistent back or knee pain was usually sent to physical therapy: a course of clinic appointments, plus exercises to keep doing at home between visits. Appointments competed with work, and pain, uncertainty and other demands made the home routine hard to keep up. A self-insured employer paid those medical claims itself, including surgery that exercise might have avoided, and musculoskeletal conditions cost US employers about $100 billion a year. The employer had money at stake but no practical way to help employees follow the treatment it was paying for H1 H3 HGX-5.
Hinge Health
Hinge Health picked joint and back pain, where guided home exercise can replace paid therapy visits, sold it through the health plans employers already buy from, then automated care so each new member adds little clinician time.
How Hinge Health won
- 1 · 2014–16MSK focus: home exercise replaces paid careSensor-guided home exercise with coaching, sold to self-insured employers who pay the claims it can save.Focus Strategy
- 2 · 2017–23Trials and claims ROI for benefits buyersKnee (2018) and back (2019) trials, then claims studies showing $2,387 saved per member and a 2.4x return.Trust
- 3 · 2017–25Sell through health plans, PBMs and consultantsFrom Castlight in 2017 to 60+ partners and 82% of revenue in 2025; Hinge wins most employers inside each partner.Channel Partners
- 4 · 2020–24Default MSK vendor, then enroll more membersUsually the only digital MSK provider a client offers; paid per engaged member; enrollment yield 2.9% to 3.4%.Land and Expand
- 5 · 2023–Scale economies in automated carePhone-camera guidance replaced sensor kits; care-team hours about 97% below clinic PT; GAAP gross margin 66% to 80%.Scale economies
Versus Omada Health: Omada built human coaching for diabetes and other chronic conditions and added MSK later HGX-10 OM2. Hinge built MSK care that software could deliver, so its costs grew more slowly than its membership HGX-8.
Arena: Market Conditions Before Hinge Health
How each step happened
Step 1 of 5 · 2014–16
MSK focus: home exercise replaces paid care
Hinge's founding choice was the condition. Both founders had been through long rehabilitation, and their first prototype, homemade sensors and an Android app, went to an Oxford receptionist who could not take time off work for appointments H2. Joint and back pain is treated mostly with exercise, and exercise can be guided at home. A program that got people doing it without clinic visits would replace care someone was already paying for HGX-5.
After testing other routes in the UK, including selling direct to athletes, the founders turned to large US self-insured employers, which pay their employees' medical claims themselves HGX-1. That buyer had a budget reason to care, and Hinge's early pitch was savings from surgery avoided HGX-5. The first US client launched in 2016 H6. Hinge sold a finished service, not an app: a 12-week program with wearable sensors, a tablet and coaching HGX-5 H3, run by a clinical team Mecklenburg says was deliberately sized at ten times rivals' HGX-1. In 2024 the independent Peterson Health Technology Institute (PHTI) found that digital programs guided by physical therapists matched in-person therapy on pain and function at lower total spending HGX-11. That substitution is what step 2 turned into a savings case.
Rivals Omada started in the Diabetes Prevention Program and entered MSK later, by acquiring Physera HGX-10 HGX-13; in 2024 PHTI found that digital diabetes tools, Omada's included, raised spending while lowering blood sugar by too little to matter clinically HGX-12. For most employees the MSK alternative was clinic physical therapy, where appointments and home exercise both competed with work H1.
Step 2 of 5 · 2017–23
Trials and claims ROI for benefits buyers
Employers and health plans buy care on evidence, so Hinge built a record buyers could check. A randomized trial of its knee program, run in 2017 and published in 2018, reported better pain and function than education and usual care H4, and a 2019 trial in chronic low back pain followed at 12 US sites HGX-3.
What buyers weighed most was savings in their own medical claims. A 2022 analysis across 136 employer groups estimated $2,387 in savings per enrolled member HGX-4, and Hinge's 2023 Employer Claims Study put the return at 2.4 times the program's cost H6. Hinge offers most clients performance guarantees on engagement, member-reported outcomes and return on investment H6. A benefits buyer could treat Hinge as a way to save money rather than an added perk, and a health plan could vet it once for many employers. Blue Cross Blue Shield of Massachusetts (BCBSMA) did exactly that after what Perez called "an extensive diligence process" HGX-3.
Rivals PHTI rated the physical-therapist-guided programs of Omada, Sword and Vori comparable to Hinge's HGX-11, and Sword won Danaher after a formal evaluation H14. Evidence qualified Hinge to be bought; rivals could qualify too.
Step 3 of 5 · 2017–25
Sell through health plans, PBMs and consultants
Perez named the next problem in 2019: "A lot of startups might build a great solution that has strong clinical outcomes, but they can't reach members" HGX-3. Hinge's answer was to sell through the companies employers already buy benefits from. Castlight added it to its pre-integrated vendors in 2017, which simplified contracting and implementation for Castlight's employers H5. BCBSMA offered it to self-insured employers with 1,000 or more staff, and the benefits consultant Willis Towers Watson became a partner HGX-3.
By the end of 2024 Hinge had over 50 partners, including four of the five largest national health plans by self-insured lives and the three largest pharmacy benefit managers (PBMs), and partner contracts produced 79% of revenue H6. Employers prefer buying through their health plan, where contracting and implementation are already set up, and when Hinge signs a partner it typically wins "a large majority of the employers using that partner who go on to select a digital MSK solution" H6. By 2025 it had more than 60 partners, and 82% of revenue came through them H9.
The same route gives partners bargaining power. HCSC, Elevance and Aetna each accounted for more than 10% of 2025 revenue, and none has to work with Hinge exclusively H9.
Rivals Omada sat on the same BCBSMA menu HGX-3 and also sells through health plans and PBMs, where two Cigna affiliates accounted for 32% and 33% of its 2025 revenue OM2. Both could use the channel; Hinge's edge was winning most employers inside each partner H6.
Step 4 of 5 · 2020–24
Default MSK vendor, then enroll more members
Winning inside the channel made Hinge the default choice. The company said in 2020 that four in five employers offering digital MSK care used Hinge HGX-2, and in 2022 that it had passed 1,000 employer customers HGX-4. Once a client signs, Hinge is most often the only digital MSK provider offered to its employees, for an average term of three years H6.
Pricing turned each contract into a population to enroll. Clients pay only for members who engage H6, so an employer takes little risk in adding the benefit, and Hinge earns more only by getting more employees to start. New marketing formats tested in 2024 raised membership applications per impression from existing clients by 36% in six months H6. Annual yield, members as a share of eligible employees and dependents, rose from 2.9% in 2022 to 3.4% in 2024, and net dollar retention, a year's billings from existing clients against the year before, reached 117% H6. Most of 2025's 51% revenue growth came from existing clients H9.
Rivals Omada launched its MSK program in 2020, with physical therapists seen by video, as one of several programs it sells to the same client alongside diabetes, hypertension and GLP-1 care OM2. It reports 90% client retention over three years H12.
Step 5 of 5 · 2023–
Scale economies in automated care
Automation made the members enrolled in step 4 cheap to serve. Hinge first shipped each member a kit with a tablet and wearable sensors; TrueMotion, launched in 2023, replaced the sensors with the camera on the member's own phone H11 H9. Bessemer says this "bring your own device" approach gave the business "SaaS-like margins" H11. Hinge estimates that its platform cut human care-team hours against traditional physical therapy by about 95% in 2024 and 97% in 2025 H6 H9, and in 2025 it served 47% more members with flat care-team costs HGX-8.
That is a scale economy: the software is built once and each new member adds little clinician time, so cost per member falls as membership grows. GAAP gross margin rose from 66% in 2023 to 77% in 2024 and 80% in 2025, which the filings attribute to the end of sensor inventory and to care-team and supply-chain efficiency H6 H9. It reached 86% in the second quarter of 2026 H15. Management reports an all-time-high head-to-head win rate and clients moving to Hinge from existing providers HGX-8. The lead is recent: Sword has similar motion tracking with fewer members HGX-13. Hinge's advantage is volume, and the volume comes from the channel and enrollment of steps 3 and 4.
Rivals Omada keeps health coaches and connected devices at the center of its care OM2 H12. Its gross margin rose from 61% in 2024 to 66% in 2025, and it still posted a $12M operating loss for 2025 HGX-9.
Key dates
- 2014Home prototype with sensors and an app, built in the UK HGX-5 H2
- 2016First US employer client H6
- 2017-12Castlight adds Hinge to its pre-integrated vendors H5
- 2018-04Knee trial published H4
- 2019-01BCBSMA partnership and back-pain trial HGX-3
- 2020-02Company says four in five digital-MSK employers use Hinge HGX-2
- 2021-06Sword wins Danaher after a formal evaluation H14
- 2022-101,000 employer customers; $2,387 saved per member in claims HGX-4
- 2023TrueMotion replaces wearable sensors with the phone camera H9 H11
- 2023$292.7M revenue Full year; GAAP gross margin 66% H9 H6
- 2024$390.4M revenue Full year, +33% year over year; GAAP gross margin 77%; net dollar retention 117% H9 H6
- 2024-06PHTI finds guided digital MSK care cuts spending HGX-11
- 2025$588M revenue Full year, +51% year over year; GAAP gross margin 80%; 82% of revenue through partners H9 HGX-8
- 2025-04Cigna pairs Hinge with its bone-and-joint program H8
- 2025-05Initial public offering HGX-6 H11
- 2025-1247% more members served on flat care-team costs HGX-8
- 2026-06$212.8M revenue Second quarter, +53% year over year; GAAP operating income $40.4M; 2,929 clients H15
- 2026-09Cylinder Health acquisition closes, adding digestive care H16 H15
Sources
Oldest first.
- H1 Barriers to treatment adherence in physiotherapy outpatient clinics: a systematic review. Primary source
- H3 Translating Comprehensive Conservative Care for Chronic Knee Pain Into a Digital Care Pathway. Primary source
- HGX-5 Our Investment in Hinge Health: how Digital Care for Common Injuries is Transforming Outcomes. Investor essay
- H5 Castlight Health Announces New Partnerships and Expanding Customer Base. Primary source
- H4 Effects of a 12-Week Digital Care Program for Chronic Knee Pain: Randomized Controlled Trial. Primary source
- HGX-3 Hinge Health partners with BCBS of Massachusetts, reveals results of clinical study. Trade report
- HGX-2 Hinge Health, the digital solution for chronic back and joint pain, closes $90M Series C. Trade report
- HGX-1 Gabriel Mecklenburg, Hinge Health, on nailing product market fit in the employer health market. Podcast summary
- H14 Sword raises $85M Series C to transform musculoskeletal care. Primary source
- HGX-4 Hinge Health surpasses 1,000 enterprise customers now accessible to 21 million lives. Company release
- HGX-12 New Report Finds That Digital Diabetes Management Tools Fail to Deliver Meaningful Health Benefits to Patients While Increasing Spending. Independent assessment
- HGX-11 New Analysis: Virtual Musculoskeletal Solutions Improve Health Outcomes and Lower Costs. Independent assessment
- H2 10 years in and we’re just getting started. Primary source
- HGX-13 Hinge Health revenue, funding & growth rate. Analyst report
- H6 Registration statement on Form S-1. Primary source
- H8 A guided approach to musculoskeletal condition care improves health outcomes and lowers costs. Primary source
- H11 Hinge Health: Reimagining possibilities and better outcomes with virtual care. Investor analysis and participant account
- HGX-6 Hinge Health's IPO: a Milestone on the Mission to Transform MSK Care. Investor essay
- H12 Hinge, Omada, and the Future of Digital Health. Outside analysis
- HGX-7 Hinge Health Q3 revenue jumps 53% as company eyes M&A, new services beyond physical therapy. Trade report
- H10 TrueMotion: turning a phone camera into a 3D motion lab. Primary source
- HGX-10 Built to Bend the Curve: A Decade with Omada Health. Investor essay
- HGX-8 Hinge Health Q4 2025 earnings call transcript. Earnings call transcript
- HGX-9 Omada Health Reports Fourth Quarter and Full-Year 2025 Results. Filing
- H9 2025 annual report on Form 10-K. Primary source
- OM2 2025 Form 10-K. Annual report
- H15 Second quarter 2026 financial results. Primary source
- H16 Hinge Health officially welcomes Cylinder Health. Primary source
- H7 Benefits Update. Primary source